Opus Genetics IRD Ratios & Valuation
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Operating margin | -359.1%-87.2pp | -271.9%+173pp | -445.4%-24.7pp | -420.7%+50.3pp | -471%+93.7pp | |
| Net margin | -892.4%-543pp | -349.3%+117pp | -466.1%-88.2pp | -377.9%+51.5pp | -429.4%+94.0pp | |
| Efficiency | ||||||
| Asset turnover | 0.2×-0.1× | 0.3×-0.1× | 0.4×0.0× | 0.4×+0.1× | 0.3×0.0× | |
| Liquidity | ||||||
| Current ratio | 7.1×+0.7× | 6.4×+5.2× | 1.2×-0.7× | 1.9×-0.1× | 2×-1.3× | |
| Per Share | ||||||
| Book value per share | -$0.53-314% | $0.25+192% | $0.08-69.4% | $0.28+84.2% | $0.15-40.5% | |
| Valuation | ||||||
| Market capitalization | $307.14M+442% | $138.62M+40.2% | $98.85M+79.4% | $55.1M+24.8% | $44.15M+17.5% | |
| Price / sales | 25.6×+21.5× | 9.8×+3.0× | 6.8×+3.2× | 3.6×+0.3× | 3.2×-0.2× |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where do Opus Genetics's ratios come from?
- Every ratio is computed from Opus Genetics's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
